Mersana Therapeutics to Present at Upcoming Investor Conferences
Rhea-AI Summary
Mersana Therapeutics (NASDAQ: MRSN), a clinical-stage biopharmaceutical company specializing in antibody-drug conjugates (ADCs) for cancer treatment, has announced its participation in two upcoming investor conferences. The company will participate in a fireside chat at the TD Cowen 6th Annual Oncology Innovation Summit on May 27, 2025, at 2:00 p.m. ET, and deliver a presentation at the Goldman Sachs 46th Annual Global Healthcare Conference on June 9, 2025, at 2:00 p.m. ET. Both events will be webcast live and available on Mersana's website, with replays accessible for approximately 90 days.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, MRSN gained 1.30%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
CAMBRIDGE, Mass., May 20, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that members of management will participate in the following upcoming investor events:
- TD Cowen 6th Annual Oncology Innovation Summit
Format: Fireside chat
Date/Time: Tuesday, May 27, 2025, at 2:00 p.m. Eastern Time - Goldman Sachs 46th Annual Global Healthcare Conference
Format: Presentation
Date/Time: Monday, June 9, 2025, at 2:00 p.m. Eastern Time
Live webcasts of these events will be available on the Investors & Media section of Mersana’s website at www.mersana.com. Archived replays will be available for approximately 90 days following the events.
About Mersana Therapeutics
Mersana Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel antibody-drug conjugates (ADCs) and driven by the knowledge that patients are waiting for new treatment options. The company has developed proprietary cytotoxic (Dolasynthen) and immunostimulatory (Immunosynthen) ADC platforms that have generated a pipeline of wholly-owned and partnered product candidates with the potential to treat a range of cancers. Its pipeline includes Emi-Le (emiltatug ledadotin; XMT-1660), a Dolasynthen ADC targeting B7-H4, and XMT-2056, an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2). Mersana routinely posts information that may be useful to investors on the “Investors & Media” section of its website at www.mersana.com.
Contact:
Jason Fredette
617-498-0020
jason.fredette@mersana.com
FAQ
What investor conferences will Mersana Therapeutics (MRSN) attend in May-June 2025?
How can investors access Mersana Therapeutics' (MRSN) conference presentations?
What is Mersana Therapeutics' (MRSN) main business focus?
What type of presentation will MRSN give at each conference?
